tiprankstipranks
Biogen downgraded to Hold from Buy at Jefferies
The Fly

Biogen downgraded to Hold from Buy at Jefferies

Jefferies downgraded Biogen (BIIB) to Hold from Buy with a price target of $180, down from $250. The firm sees a “tough setup” into 2025 for Biogen with modest Leqembi and Skyclarys US. It see a “real need” for more pipeline and “serious” business development to get investors re-engaged in the shares. Investors haven’t bought into Leqembi and Jefferies doubt 2025 convinces the Street, the analyst tells investors in a research note.

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App